Monica Gordon-Alonso
Director, Oncology Biologics Innovation GSK
Dr. Monica Gordon-Alonso earned her PhD in Molecular Immunology from the Autonomous University of Madrid in 2009, specializing in T cell membrane organization and its implications for HIV infection. She then pursued postdoctoral research in Onco-Immunology at the de Duve Institute in Brussels. In 2017, she led a collaboration between the Institute and Nouscom, a cancer vaccine biotechnology company. Since 2018, Dr. Gordon-Alonso has transitioned to industry, holding roles at F-star, a biotech focused on bispecific antibodies, and subsequently contributing to Oncology Cell Therapy at AstraZeneca and GSK. Since 2022, she has concentrated on oncology-targeted antibody-based therapies. Currently, Dr. Gordon-Alonso is focused in integrating new technologies and targets into GSK’s pipeline, ensuring an innovative and differentiated portfolio.
Seminars
Given that many tumour-associated antigens are also expressed on healthy tissues, on-target/off-tissue toxicity remains a significant challenge for TCE therapies. This workshop will explore next-generation engineering strategies that are reshaping TCE design to enhance selectivity and enable safer targeting of difficult antigens.
- Incorporating costimulatory domains and conditional activation systems to enhance therapeutic efficacy while minimising systemic toxicit
- Evaluating avidity-based engineering and multi-targeting strategies to achieve greater tumour selectivity and reduce engagement with healthy tissues
- Assessing the practical challenges of each engineering approach including manufacturing complexity, scalability, immunogenicity risk, and preclinicalto-clinical translation
